These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35836754)

  • 1.
    Li G; Tang LJ; Zhu PW; Huang OY; Rios RS; Zheng KI; Chen SD; Ma HL; Targher G; Byrne CD; Pan XY; Zheng MH
    J Clin Transl Hepatol; 2022 Jun; 10(3):439-448. PubMed ID: 35836754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.
    Tang S; Zhang J; Mei TT; Guo HQ; Wei XH; Zhang WY; Liu YL; Liang S; Fan ZP; Ma LX; Lin W; Liu YR; Qiu LX; Yu HB
    BMC Med Genet; 2020 Aug; 21(1):163. PubMed ID: 32811452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD.
    Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Belt P; Liang T; Liu W; Chalasani N
    Am J Gastroenterol; 2021 May; 116(5):994-1006. PubMed ID: 33306506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis.
    Dai G; Liu P; Li X; Zhou X; He S
    Medicine (Baltimore); 2019 Feb; 98(7):e14324. PubMed ID: 30762732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
    Lee SS; Byoun YS; Jeong SH; Woo BH; Jang ES; Kim JW; Kim HY
    Dig Dis Sci; 2014 Dec; 59(12):2967-74. PubMed ID: 25069572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.
    Hotta K; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A
    BMC Med Genet; 2010 Dec; 11():172. PubMed ID: 21176169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.
    Grimaudo S; Pipitone RM; Pennisi G; Celsa C; Cammà C; Di Marco V; Barcellona MR; Boemi R; Enea M; Giannetti A; Spatola F; Marchesini G; Craxì A; Petta S
    Clin Gastroenterol Hepatol; 2020 Apr; 18(4):935-944.e3. PubMed ID: 31419571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.
    Rosso C; Caviglia GP; Birolo G; Armandi A; Pennisi G; Pelusi S; Younes R; Liguori A; Perez-Diaz-Del-Campo N; Nicolosi A; Govaere O; Castelnuovo G; Olivero A; Abate ML; Ribaldone DG; Fariselli P; Valenti L; Miele L; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3314-3321.e3. PubMed ID: 37149016
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
    Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
    Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population.
    Narayanasamy K; Karthick R; Panneerselvam P; Mohan N; Ramachandran A; Prakash R; Rajaram M
    J Gene Med; 2020 Apr; 22(4):e3160. PubMed ID: 31945251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.
    Sookoian S; Pirola CJ
    Hepatology; 2011 Jun; 53(6):1883-94. PubMed ID: 21381068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events.
    Rüschenbaum S; Schwarzkopf K; Friedrich-Rust M; Seeger F; Schoelzel F; Martinez Y; Zeuzem S; Bojunga J; Lange CM
    Hepatol Commun; 2018 Jul; 2(7):798-806. PubMed ID: 30027138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.
    Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H
    Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease.
    Wang JZ; Cao HX; Chen JN; Pan Q
    World J Clin Cases; 2018 Aug; 6(8):167-175. PubMed ID: 30148144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].
    Bing H; Wang W; Li YL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):156-162. PubMed ID: 33685085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.